SLC5A2 and diabetes mellitus: Taken together, these observations led to our hypothesis that, independent of diabetes, SGLT2 inhibition would cause pro-metabolic programming of the failing heart, thereby leading to improved mitochondrial function and amelioration of aspects of the phenotype that are due to deficient ATP production and/or excessive ROS production.